Research
Hormonal
Liraglutide 3 mg daily is an effective pharmacological intervention for chronic weight management, producing a mean 5.2 kg placebo-subtracted weight loss at 1 year, with generic availability potentially improving cost-effectiveness in resource-limited settings.
If you have obesity and meet the BMI criteria, ask your doctor about liraglutide. It is a daily injection that helps suppress appetite and has been shown to help people lose an average of 5.2 kg more than placebo. Generic versions may be available, making it more affordable in some regions.
GoodSupportsHIGH confidence
A meta-analysis [73] revealed that liraglutide produced a mean 5.2 kg placebo-subtracted weight loss at 1 year, with 63% of participants achieving a ≥ 5% weight loss, inclusive of 34% of participants who lost ≥ 10% of initial weight. The recent expiration of liraglutide's patent protection in multiple countries opens the door for generic versions, which may become a cost-effective GLP-1 RA option in resource-limited settings.
Why this rating
Supported by multiple prominent RCTs (LEADER, SCALE series) and a meta-analysis.
Source
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Stefan D. Anker et al. · Journal of Cachexia Sarcopenia and Muscle · 2026
DOI 10.1002/jcsm.70167
clinical_guideline
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide 2.4 mg once weekly is a highly effective treatment for obesity, leading to an average 14.9% body weight loss in nondiabetic adults over 68 weeks, and reduces major adverse cardiovascular events (MACE) in patients with obesity without diabetes.Strong
- Lifestyle modifications, specifically calorie restriction of 500-750 kcal/day and ≥ 150 minutes of exercise per week, are the first-line treatment for obesity, though long-term maintenance is challenging without pharmacological or surgical support.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →